Estudo randomizado | Atezolizumabe adjuvante não melhorou os desfechos de pacientes com carcinoma de célula renal sob risco aumentado de recorrência após a ressecção.

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Comentários:

Adjuvant atezolizumab falls short in renal cell carcinoma – Urology Times

IMmotion010 does not support adjuvant atezolizumab in intermediate-, high-risk RCC – medwire News

Comentário do autor no Twitter (fio – clique para saber mais)

Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY pic.twitter.com/klAYWAQVwV

— Sumanta Pal (@montypal) September 10, 2022